Caricamento...
The systemic implication of novel non-statin therapies in cardiovascular diabetology: PCSK9 as a case model
PCSK9, like other novel non-statin drugs were primarily developed to help patients achieve low-density lipoprotein cholesterol targets, especially in patients with dyslipidemia not achieving lipid goals with statins due to poor tolerance or inadequate response. PCSK9 inhibitors, in addition to modul...
Salvato in:
| Pubblicato in: | Cardiovasc Endocrinol Metab |
|---|---|
| Autori principali: | , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Wolters Kluwer Health
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7673769/ https://ncbi.nlm.nih.gov/pubmed/33225229 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/XCE.0000000000000204 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|